Development, Commercialization and Supply Agreement - Additional Information (Detail)	1 Months Ended							3 Months Ended		12 Months Ended
	Jan. 31, 2021 USD ($)	Feb. 29, 2020 USD ($)	Jan. 31, 2020 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Mar. 31, 2016 USD ($)	Feb. 28, 2015 USD ($)	Mar. 31, 2021 USD ($) Item	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2019 USD ($)
License And Collaboration Agreements [Line Items]
Revenue recognized related to upfront and milestone payments								$ 662,000	$ 2,789,000
Licenses revenue								142,170,000	154,993,000
Deferred revenue								17,970,000	21,807,000	$ 18,632,000		$ 20,846,000
Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue								$ 141,383,000	152,204,000
Mochida | In-licenses
License And Collaboration Agreements [Line Items]
Milestones payment	$ 1,000,000.0									1,000,000.0
Mochida | In-licenses | Research and Development Expense
License And Collaboration Agreements [Line Items]
Upfront payment											$ 2,700,000
Edding | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received							$ 15,000,000.0
Number of indications of the regulatory milestone events relating to the submission and approval | Item								3
Amounts to be received upon achievement of the regulatory milestone events								$ 33,000,000.0
Sales-based milestone event payment								120,000,000.0
Revenue recognized related to upfront and milestone payments								300,000	600,000
Deferred revenue								10,500,000		10,800,000
Edding | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue								6,400,000		6,100,000
Edding | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone								153,000,000.0
Amounts to be received upon achievement of the regulatory milestone events								15,000,000.0
Sales-based milestone event payment								50,000,000.0
Edding | Out-licenses | Minimum
License And Collaboration Agreements [Line Items]
Amounts to be received upon achievement of the regulatory milestone events								2,000,000.0
Sales-based milestone event payment								5,000,000.0
Edding | Out-licenses | Clinical Trial Application
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment						$ 1,000,000.0
Biologix FZCo | Out-licenses
License And Collaboration Agreements [Line Items]
Revenue recognition period of non-refundable up-front payment						10 years
Biologix FZCo | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue								500,000
HLS | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received					$ 5,000,000.0
Non-refundable milestone payment		$ 2,500,000	$ 3,800,000	$ 2,500,000	$ 2,500,000
Revenue recognized related to upfront and milestone payments								300,000	2,200,000
Deferred revenue								6,800,000		7,100,000
Non-refundable up-front received period					6 months
Non-refundable milestone payment received					$ 3,800,000
HLS | Out-licenses | Health Canada
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment					2,500,000
HLS | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue								$ 6,900,000		$ 6,600,000
HLS | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue									$ 6,700,000
HLS | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone					$ 50,000,000.0